The Europe Synthetic Small Molecule API Market would witness market growth of 5.2% CAGR during the forecast period (2022-2028).
It takes a long time to develop a new drug because there is only a 1:10,000 probability that a novel molecule will be used as a drug. To improve the likelihood of discovering novel lead compounds, a large number of tiny molecules that differ not only in their appendages but also in their chemical skeleton are required.
Organic chemists have developed a wide range of diverse synthetic techniques since the advent of medicinal chemistry as a scientific field in 1930 to the current day to enhance the quality and quantity of tiny molecules that make up a library. It provides an overview of the key methodologies, emphasizing historical context while also covering solid-phase approaches, diversity-oriented synthesis, combinatorial chemistry, and biology-oriented synthesis.
Small molecule medications have traditionally dominated the treatment of human disease. Small molecules can have a wide range of different modes of action and are utilized to treat a wide range of illnesses and ailments. Tiny compounds can act as efficient enzyme inhibitors and allosteric regulators and can target auxiliary variable or intracellular receptors in the cytosol, nucleus, and central nervous system due to their small size and typical physiochemical features. Small molecules continue to be the mainstay of an ever-expanding medicinal toolbox despite apparent limitations and a recent revival.
The growth in demand for molecular quality controls in Europe is primarily driven by the increase in cancer research and associated biomarkers. A study presented at the annual conference of the European Society of Medical Oncology predicts a 21% increase in cancer incidence between 2020 and 2040. The development of the AVENIO Tumor Tissue CGP Kit, which Roche announced would be available in October 2021 and which is intended to assist labs in enhancing internal cancer research, is evidence that efforts to identify biomarkers are also growing. It is expected that Europe will continue to play a significant role in molecular quality controls in the foreseeable future.
The Germany market dominated the Europe Synthetic Small Molecule API Market by Country in 2021; thereby, achieving a market value of $12,468.4 million by 2028. The UK market would witness a CAGR of 4.3% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 6% during (2022 - 2028).
Based on Manufacturer, the market is segmented into In-house and Outsourced. Based on Application, the market is segmented into Cardiology, Oncology, CNS & Neurology, Endocrinology, Orthopedic, Gastroenterology, Pulmonology, Nephrology, Ophthalmology, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Synthetic Small Molecule API Market will Hit $187.8 Billion by 2028, at a CAGR of 5.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck & Co., Inc., Viatris, Inc., Cipla Limited, Teva Pharmaceuticals Industries Ltd., Sun Pharmaceuticals Industries Ltd., AbbVie, Inc., Bristol Myers Squibb Company, Boehringer Ingelheim International GmbH, Aurobindo Pharma Limited and Albermale Corporation.
By Manufacturer
By Application
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 